SystImmune Competitors and Similar CompaniesClear all
SystImmune's competitors and similar companies include Ikena Oncology, Barinthus Biotherapeutics, Seagen and Legend Biotech.
 Ikena Oncology Ikena Oncology (formerly Kyn Therapeutics) is a biotechnology company that discovers and develops biomarker-driven therapies for cancer treatment. |  Barinthus Biotherapeutics Barinthus Biotherapeutics (formerly known as Vaccitech) is a T-cell immunotherapy company developing products to treat and prevent cancer and infectious diseases. |  Seagen Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer. |  Legend Biotech Legend Biotech is a biopharmaceutical company engaged in the discovery and development of cell therapies for oncology and other indications.
| ||
Founding Date | Founding Date 2014 | Founding Date 2016 | Founding Date 2016 | Founding Date 1998 | Founding Date 2014 |
Type | Type Private | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Redmond, US HQ | Locations Boston, US HQ | Locations Oxford, GB HQ | Locations Bothell, US HQ Mississauga, CA Hørsholm, DK Rueil Malmaison, FR München, DE Milano, IT Schiphol, NL see more | Locations Somerset, US HQ Ghent, BE Nanjing, CN Hong Kong, HK Dublin, IE Piscataway, US |
Employees | Employees 841% increase | Employees 5052% increase | Employees 33 | Employees 3,25622% increase | Employees 2,90012% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 82.5 m | Valuation ($) 57.2 m | Valuation ($) N/A | Valuation ($) 8.4 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $800k (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $2b (FY, 2022) | Revenue (est.) $1b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $410.1m (FY, 2022) | Cost of goods $408.1m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $16k (FY, 2025) | Gross profit $1.6b (FY, 2022) | Gross profit $620.8m (FY, 2025) |
Net income | Net income N/A | Net income ($45.3m) (FY, 2025) | Net income ($66.5m) (FY, 2025) | Net income ($610.3m) (FY, 2022) | Net income ($296.8m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 76m | Total funding raised $ 49m | Total funding raised $ 195.1m | Total funding raised $ 164m | Total funding raised $ 150.5m |
For sources of this data, please see the company profile
View Company Profiles
Ikena Oncology
HQ
Boston, US
Employees
50
Ikena Oncology (formerly Kyn Therapeutics) is a biotechnology company that discovers and develops biomarker-driven therapies for cancer treatment.
View companyBarinthus Biotherapeutics
HQ
Oxford, GB
Employees
33
Barinthus Biotherapeutics (formerly known as Vaccitech) is a T-cell immunotherapy company developing products to treat and prevent cancer and infectious diseases.
View companySeagen
HQ
Bothell, US
Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer.
View companyLegend Biotech
HQ
Somerset, US
Employees
2,900↑ 12% increase
Legend Biotech is a biopharmaceutical company engaged in the discovery and development of cell therapies for oncology and other indications.
View company